Innovation Ventures Search Results
Narrow Your Results
Filter
Technology PatentStatus
- All (4)
- Issued Patent (1)
- National Phase Entry (2)
- PCT Filing (0)
- Provisional Filing (1)
- US Non-Provisional Filing (0)
Technology Categories
- All (4)
- Diagnostics (0)
- Educational Tools and Consumer Products (0)
- Medical Devices (0)
- Other (0)
- Research Tools (0)
- Software (0)
- Therapeutics (4)
Technology Stage Of Development
- All Results (4)
- Cell and Gene Therapy (0)
- Organoids (0)
- Other Biologics and Macromolecules (0)
- Small Molecule (4)
- Vaccines (0)
Results (4)
Combination Therapy for Leukemia and Solid Tumors
A pharmaceutical therapy that has demonstrated, in vivo, the ability to eliminate leukemic, lung adenocarcinoma and lung squamous carcinoma cells.
Novel DUSP1 and FLT3-JAK2-IKK1 Degraders for Treating Relapsed and Recurrent Leukemia
Next-generation orally bioavailable degrader programs targeting DUSP1 and NFKB1 suppress JAK-STAT and NFκB signaling to restore treatment sensitivity in relapsed and refractory leukemia and potentially other cancers.
Novel Small Molecule RAC-Pathway Inhibitor for the Treatment of Cancer
Our proprietary inhibitor binds to VAV3 thereby inhibiting the activation of RAC downstream of several oncogenes.
Targeted inhibition of UBE2N as a therapeutic approach in myeloid malignancies
Pharmacologic and genetic inhibition of UBE2N suppresses the function and viability of MDS/AML cells lines and patient samples. A commercially available and a novel compound has been identified.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
